A new drug, Daromun, which is injected directly into the tumor, has demonstrated significant efficacy in reducing the risk of recurrence and metastasis of locally advanced melanoma.
The results of the Pivotal study, presented at the Innovate congress in Naples, are very promising and open new avenues in the treatment of this serious form of cancer.
“The treatment carried out directly on the tumor mass “triggers a local and systemic immune response”, the oncologist explained Paul Ascierto, and is effective both in “patients who have not received any therapy before, or in cases previously subjected to systemic immunotherapy”.
How does Daromun work?
Daromun is a combination of two cytokines, interleukin 2 (IL-2) and tumor necrosis factor (TNF), conjugated to a monoclonal antibody that targets a specific isoform of fibronectin present in the tumor.
This combination triggers a local immune response against the tumor, which also has distant effects, preventing the appearance of metastases.
What does the Pivotal study say?
The Pivotal study involved 256 patients with locally advanced resectable melanoma. Patients were divided into two groups: one received Daromun injection into tumor lesions for 4 weeks before surgery, the other underwent surgery directly. The results showed:
A 41% reduction in the risk of recurrence in patients treated with Daromun compared to those who underwent surgery alone.
A 40% reduction in the risk of distant metastases in patients treated with Daromun.
Daromun: A further opportunity for patients with locally advanced melanoma
The results of the Pivotal study demonstrate that Daromun is an effective and safe treatment for locally advanced melanoma. This drug represents an additional therapeutic opportunity for patients with this form of cancer, offering them real hope of improving their prognosis.
Daromun: When will it be available?
Philogen, the company that developed Daromun, has already submitted a marketing authorization request for this drug to the EMA. The company hopes to soon offer Daromun to patients with locally advanced melanoma, including those who have already been treated with systemic immunotherapy.
An important step forward in the fight against melanoma
The results of the Pivotal study represent a major step forward in the fight against melanoma. Daromun has the potential to significantly improve the lives of patients with this form of cancer, offering them new hope for a cure.
EDITORIAL TEAM
Choose the social channel you want to subscribe to